ACE Technology Guidances communicate recommendations from the MOH Drug Advisory Committee or the MOH Medical Technology Advisory Committee on the funding status and appropriate use of drugs, vaccines or medical technologies that have been evaluated by ACE. The guidances also include the Committee’s rationale for the funding recommendations, and key clinical and economic evidence which informed their deliberations. Plain English Summaries (PES) to explain ACE Technology Guidances are available for patients and the public.

Published on 01 Apr 2022
Last Updated on 01 Apr 2022
A- A+
Guidance Recommendations
The Ministry of Health's Drug Advisory Committee has recommended:
  • Brinzolamide 1% eye drops; and
  • Brinzolamide/timolol 1%/0.5% eye drops

in line with their registered indications for reducing intraocular pressure in patients with open-angle glaucoma or ocular hypertension, in view of acceptable price proposals from the manufacturer.

Subsidy status

Brinzolamide 1% and brinzolamide/timolol 1%/0.5% eye drops are recommended for inclusion on the MOH Standard Drug List (SDL) for the abovementioned indications.

SDL subsidy does not apply to brinzolamide/brimonidine 1%/0/0.2% eye drops in view of unacceptable price proposal from the manufacturer.

Carbonic anhydrase inhibitor eye drops for treating open-angle glaucoma or ocular hypertension (1 Apr 2022)